Nephros Announces Publication of Observational Trial of DSU-D in a Hospital-Based Dialysis Facility

RIVER EDGE, N.J.--()--Nephros, Inc. (OTCQB:NEPH),(the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with hemodialysis machines for the treatment of End Stage Renal Disease patients, announced today that data about Nephros’ DSU-D ultrafilter was published online in Case Reports in Nephrology and Dialysis.

Title: Benefits of the Nephros Dual Stage Ultrafilter in Chronic Hemodialysis Patients: Evidence for Improved ESA Responsiveness

The full study can be found via the following weblink: https://www.karger.com/Article/FullText/443328

Nephros Challenge Ending Soon

In September 2015, the Company announced the Nephros Challenge, a program offering a money-back guarantee to encourage dialysis clinics to evaluate the performance improvement potential from using Nephros ultrafilters. The ultrafilters are used on the water and bicarbonate concentrate lines which feed into a hemodialysis machine. The ultrafilters retain particles as small as five nanometers (5nm), preventing bacteria, viruses and endotoxins from entering the machine. Nephros’ proprietary filter fiber provides superior protection and enables a five log reduction in levels of endotoxin, which is a key contributor to vascular inflammation in dialysis patients. Nephros ultrafilters are FDA 510(k) cleared for a 12-month product life when used in dialysis clinics.

The Nephros Challenge program continues until March 31, 2016. For dialysis clinics that wish to enroll in the Nephros Challenge before the promotion ends, they can contact their water system provider or contact Nephros at TheChallenge@Nephros.com.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company’s website at www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Nephros Challenge and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contacts

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com

Contacts

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com